Conference report: Interim analysis of phase III ORIENT-11 trial of sintilimab in combination with pemetrexed (PM) and platinum chemotherapy (PC) as first-line treatment in people with nonsquamous non-small cell lung cancer without sensitive EGFR mutation or ALK rearrangement

RCT (n= 397) met pre-defined efficacy criteria; after median follow up of 8.9 months, addition of sintilimab to PM and PC linked to statistically significant improvement in progression-free survival vs. addition of placebo (8.9 v 5.0 months; HR 0.482;95%CI, 0.362-0.643;p<0.00001)

SPS commentary:

Sintilimab is an immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1/ PD-Ligand 1 pathway and reactivates T-cells to kill cancer cells.

Biospace Inc.